Movement Disorders Clinical Trial
Official title:
A Feasibility Study of MRgFUS in the Treatment of Therapy-Resistant Tremor-Related Patients With Low SDR Value
A study to evaluate the effectiveness and safety of ExAblate transcranial MRgFUS Thalamotomy treatment of medication refractory tremor-related diseases subjects with low skull density ratio (SDR) value. Essential tremor (ET) and Parkinson disease (PD) are the most prevalent tremor disorders. ET, considered as a pure tremor disease, is characterized by upper limb intention or postural tremor, while PD is characterized by a variety of motor and non-motor symptoms, among them rest tremor. A number of studies have demonstrated that Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is a minimally invasive and effective procedure suitable for medication-refractory tremor in patients with ET and patients with PD. However, the skull is the main barrier to MRgFUS thalamotomy therapy and patients are screened by calculating SDR value before treatment. The US FDA recommended SDR value >0.45±0.05 as the inclusion criterion for screening patients with tremor treated by MRgFUS system. However, about 20%-50% of patients with SDR value are lower than this standard, which makes this part of patients excluded and unable to accept this treatment with many advantages such as non-invasive, no need for general anesthesia, and no need for hardware implantation. Therefore, this study intended to evaluate the safety and effectiveness of MRgFUS thalamotomy in the treatment of tremor-related patients with low SDR value, so as to provide clinical basis for more patients with tremor to benefit from this treatment.
Patients: Patients with medication-refractory ET and PD were included. Baseline materials, clinical rating scale for tremor (CRST) , treatment parameters(energy, power, duration time, temperature, target location) , associated adverse effects were recorded. Imaging protocols: T2; T2 Flair; DWI; ESWAN; MRS; 3D ASL 2.0s; 3D-T1; DTI; rs-functional MRI Imaging evaluation: 1. Lesion appearance and volume are measured by T2, T2 Flair, DWI, ESWAN, 3D-T1; 2. ESWAN and MRS manifests the changes of iron deposition and metabolism #respectively; 3. ASL shows regional cerebral blood flow associated with the procedure; 4. DTI demonstrates the destruction of white matter integrity. 5. Rs-functional MRI reflects alterations of resting-state brain activity. Treatment: MRgFUS thalamotomy Follow-up: Baseline (MRI+clinical evaluation); 1-day, 1-month, 3-months, 6-months,1-year, 2-years (MRI+clinical evaluation). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05623644 -
Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy
|
||
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Recruiting |
NCT05973929 -
Movement Disorders in Multiple Sclerosis Patients
|
||
Terminated |
NCT02823158 -
Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
|
N/A | |
Enrolling by invitation |
NCT01210781 -
Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation
|
||
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00037167 -
Effects of Exercise Poles on Older Adults During Exercise Walking
|
Phase 1/Phase 2 | |
Recruiting |
NCT04784494 -
MST for Parkinson's Disease
|
N/A | |
Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
Recruiting |
NCT04061135 -
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders
|
N/A | |
Recruiting |
NCT04176692 -
The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements
|
||
Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
Completed |
NCT00500994 -
Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures
|
Early Phase 1 | |
Completed |
NCT04536987 -
Robot Therapy for Rehabilitation of Hand Movement After Stroke
|
Phase 2 | |
Recruiting |
NCT00001208 -
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
|
||
Completed |
NCT02392078 -
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
|
||
Completed |
NCT00552474 -
Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease
|
N/A | |
Not yet recruiting |
NCT05032911 -
Sensorimotor Control in People With and Without Neck Pain
|